$BIIB CEO Michel Vounatsos on current status of aducanumab filing: "We are actively engaging with the FDA as well as regulators in Europe and Japan, and we look forward to completing a regulatory filing in the US as soon as possible."
-
-
I wonder if this is key in
$BIIB argument to FDA for Aducanumab approval. Ie need to approve multiple Txs for a combo solution (with more clear efficacy). Versus starting over from scratch with combo trials?Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.